Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Signorelli D, Giannatempo P, Grazia G, Aiello MM, Bertolini F, Mirabile A, Buti S, Vasile E, Scotti V, Pisapia P, Cona MS, Rolfo C, Malapelle U; Immune-Oncology YOUNG Group. Signorelli D, et al. Among authors: scotti v. Biomed Res Int. 2019 Apr 24;2019:9056417. doi: 10.1155/2019/9056417. eCollection 2019. Biomed Res Int. 2019. PMID: 31179334 Free PMC article. Review.
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
De Giorgi U, Cartenì G, Giannarelli D, Basso U, Galli L, Cortesi E, Caserta C, Pignata S, Sabbatini R, Bearz A, Buti S, Lo Re G, Berruti A, Bracarda S, Cognetti F, Rastelli F, Fornarini G, Porta C, Turci D, Sternberg CN, Procopio G; Italian Nivolumab Renal Cell Cancer Early Access Program Group. De Giorgi U, et al. BJU Int. 2019 Jan;123(1):98-105. doi: 10.1111/bju.14461. Epub 2018 Jul 23. BJU Int. 2019. PMID: 29956884 Free article.
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
Baldini E, Lunghi A, Cortesi E, Turci D, Signorelli D, Stati V, Melotti B, Ricciuti B, Frassoldati A, Romano G, Ceresoli GL, Illiano A, Verderame F, Fasola G, Ricevuto E, Marchetti P, Pinto C, Cartenì G, Scotti V, Tibaldi C, Fioretto L, Giannarelli D. Baldini E, et al. Among authors: scotti v. Lung Cancer. 2020 Feb;140:59-64. doi: 10.1016/j.lungcan.2019.12.014. Epub 2019 Dec 20. Lung Cancer. 2020. PMID: 31881412
First-line pembrolizumab in advanced non-small cell lung cancer patients with poor performance status.
Facchinetti F, Mazzaschi G, Barbieri F, Passiglia F, Mazzoni F, Berardi R, Proto C, Cecere FL, Pilotto S, Scotti V, Rossi S, Del Conte A, Vita E, Bennati C, Ardizzoni A, Cerea G, Migliorino MR, Sala E, Camerini A, Bearz A, De Carlo E, Zanelli F, Guaitoli G, Garassino MC, Ciccone LP, Sartori G, Toschi L, Dall'Olio FG, Landi L, Pizzutilo EG, Bartoli G, Baldessari C, Novello S, Bria E, Cortinovis DL, Rossi G, Rossi A, Banna GL, Camisa R, Di Maio M, Tiseo M. Facchinetti F, et al. Among authors: scotti v. Eur J Cancer. 2020 May;130:155-167. doi: 10.1016/j.ejca.2020.02.023. Epub 2020 Mar 25. Eur J Cancer. 2020. PMID: 32220780
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, Russo GL, Signorelli D, Toschi L, Milella M, Pilotto S, Bria E, Proto C, Marinello A, Randon G, Rossi S, Vita E, Sartori G, D'Argento E, Qako E, Giaiacopi E, Ghilardi L, Bettini AC, Rapacchi E, Mazzoni F, Lavacchi D, Scotti V, Ciccone LP, De Tursi M, Di Marino P, Santini D, Russano M, Bordi P, Di Maio M, Audisio M, Filetti M, Giusti R, Berardi R, Fiordoliva I, Cerea G, Pizzutilo EG, Bearz A, De Carlo E, Cecere F, Renna D, Camisa R, Caruso G, Ficorella C, Banna GL, Cortinovis D, Brighenti M, Garassino MC, Tiseo M. Bersanelli M, et al. Among authors: scotti v. Lung Cancer. 2020 Dec;150:123-131. doi: 10.1016/j.lungcan.2020.10.008. Epub 2020 Oct 22. Lung Cancer. 2020. PMID: 33130353 Free article.
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG.
Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Verzoni E, Clemente A, Guadalupi V, Signorelli D, Tiseo M, Giusti R, Filetti M, Di Napoli M, Calvetti L, Cappetta A, Ermacora P, Zara D, Barbieri F, Baldessari C, Scotti V, Mazzoni F, Veccia A, Guglielmini PF, Maruzzo M, Rossi E, Grossi F, Casadei C, Cortellini A, Verderame F, Montesarchio V, Rizzo M, Mencoboni M, Zustovich F, Fratino L, Cinieri S, Negrini G, Banzi M, Sorarù M, Zucali PA, Lacidogna G, Russo A, Battelli N, Fornarini G, Mucciarini C, Bracarda S, Bonetti A, Pezzuolo D, Longo L, Sartori D, Iannopollo M, Cavanna L, Meriggi F, Tassinari D, Corbo C, Gernone A, Prati V, Carnio S, Giordano P, Dicorato AM, Verusio C, Atzori F, Carrozza F, Gori S, Castro A, Pilotto S, Vaccaro V, Garzoli E, Di Costanzo F, Maiello E, Labianca R, Pinto C, Tognetto M, Buti S. Bersanelli M, et al. Among authors: scotti v. Ther Adv Med Oncol. 2020 Nov 2;12:1758835920968463. doi: 10.1177/1758835920968463. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33224275 Free PMC article.
The NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC.
Perna M, Scotti V, Ciammella P, Borghetti P, D'angelo E, Levra NG, Fozza A, Mariotti M, Salvestrini V, Bertolini F, Vagge S, Taraborrelli M, Falcinelli L, Taddeo A, Rossi R, Costantino G, Frassinelli L, Filippi AR, Greco C, Franceschini D, Genovesi D, Lohr F, Magrini SM, Alongi F, Livi L, Bruni A. Perna M, et al. Among authors: scotti v. Clin Lung Cancer. 2021 Sep;22(5):e767-e773. doi: 10.1016/j.cllc.2021.02.005. Epub 2021 Feb 16. Clin Lung Cancer. 2021. PMID: 33766477
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2).
Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Clemente A, Verzoni E, Giusti R, Di Napoli M, Aprile G, Ermacora P, Catino A, Scotti V, Mazzoni F, Guglielmini PF, Veccia A, Maruzzo M, Rossi E, Grossi F, Casadei C, Ficorella C, Montesarchio V, Verderame F, Rizzo M, Guaitoli G, Fratino L, Accettura C, Mencoboni M, Zustovich F, Baldessari C, Cinieri S, Camerini A, Laera L, Sorarù M, Zucali PA, Guadalupi V, Leonardi F, Tiseo M, Tognetto M, Di Costanzo F, Pinto C, Negrini G, Russo A, Migliorino MR, Filetti M, Buti S; FICOG group (Federation of Italian Cooperative Oncology Groups). Bersanelli M, et al. Among authors: scotti v. J Immunother Cancer. 2021 May;9(5):e002619. doi: 10.1136/jitc-2021-002619. J Immunother Cancer. 2021. PMID: 34016723 Free PMC article.
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.
Tibaldi C, Mazzoni F, Scotti V, Vasile E, Pozzessere D, Stasi I, Camerini A, Federici F, Meoni G, Caparello C, Turrini M, Rossi V, Ciccone LP, Pecora I, Fantechi B, Antonuzzo L, Giannarelli D, Baldini E. Tibaldi C, et al. Among authors: scotti v. Anticancer Agents Med Chem. 2022;22(7):1278-1285. doi: 10.2174/1871520621666210727112212. Anticancer Agents Med Chem. 2022. PMID: 34315390
170 results